Peter Mills

Management

Peter specialises in licensing in the life sciences sector, working closely with world-leading scientists to commercialise their technology. He has worked across all areas of the pharmaceutical, medical device, digital health and diagnostic industries and has deep international business experience in strategic licensing, clinical trial development, business development, finance and commercialisation. Most recently, Peter managed the clinical development and finances of both Syntalogic and Syntimmune (acquired by Alexion for $1.2B) in the fields of oncology and autoimmune disease.